Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Receivables - Net: 2016-2025

Historic Receivables - Net for RedHill Biopharma (RDHL) over the last 6 years, with Jun 2025 value amounting to $5.3 million.

  • RedHill Biopharma's Receivables - Net rose 449.28% to $5.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.3 million, marking a year-over-year increase of 449.28%. This contributed to the annual value of $2.5 million for FY2024, which is 2.01% down from last year.
  • Per RedHill Biopharma's latest filing, its Receivables - Net stood at $5.3 million for Q2 2025, which was up 110.71% from $2.5 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Receivables - Net ranged from a high of $36.0 million in Q3 2022 and a low of $974,000 during Q2 2024.
  • Moreover, its 3-year median value for Receivables - Net was $2.7 million (2023), whereas its average is $3.5 million.
  • As far as peak fluctuations go, RedHill Biopharma's Receivables - Net spiked by 1,257.37% in 2021, and later slumped by 92.49% in 2023.
  • RedHill Biopharma's Receivables - Net (Quarterly) stood at $31.7 million in 2021, then climbed by 8.98% to $34.5 million in 2022, then plummeted by 92.49% to $2.6 million in 2023, then fell by 2.01% to $2.5 million in 2024, then spiked by 449.28% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q2 2025, $2.5 million for Q4 2024, and $974,000 during Q2 2024.